Analysis of HLA-G expression in renal tissue in lupus nephritis: a pilot study.


Journal

Lupus
ISSN: 1477-0962
Titre abrégé: Lupus
Pays: England
ID NLM: 9204265

Informations de publication

Date de publication:
Aug 2019
Historique:
pubmed: 12 7 2019
medline: 16 1 2020
entrez: 12 7 2019
Statut: ppublish

Résumé

The study aimed to investigate whether HLA-G antigen is expressed in the kidneys of patients affected by lupus nephritis (LN) and whether its detection in renal biopsies could be adopted as a marker of treatment response and prognosis. Thirty renal biopsies from patients with LN were selected and analyzed through immunohistochemistry. Laboratory and clinical data were retrospectively collected at baseline, 6 and 12 months and at the latest clinical appointment. A number of patients (63.3%) were treated with rituximab (RTX) +/- methylprednisolone in the induction phase. The expression of HLA-G in glomeruli, tubules and infiltrating cells was examined and compared between lupus patients who achieved either complete or partial renal response and those who did not respond to treatment. HLA-G staining was observed in the glomeruli of 20 of 30 samples from patients with LN. The expression of the antigen was detected in podocytes, along glomerular capillary walls, on parietal glomerular epithelial cells and within the juxtaglomerular apparatus. Seventy per cent of patients whose glomeruli expressed HLA-G achieved partial or complete response at 6 months and 75% at the latest available follow up compared with 30% and 40%, respectively, of those who did not show any expression. The pattern of staining in tubules and infiltrating cells was highly variable precluding any clinical correlation. This study demonstrates that HLA-G is expressed in renal tissue in LN. Our retrospective data suggest that its expression could correlate with response to treatment.

Sections du résumé

BACKGROUND BACKGROUND
The study aimed to investigate whether HLA-G antigen is expressed in the kidneys of patients affected by lupus nephritis (LN) and whether its detection in renal biopsies could be adopted as a marker of treatment response and prognosis.
METHODS METHODS
Thirty renal biopsies from patients with LN were selected and analyzed through immunohistochemistry. Laboratory and clinical data were retrospectively collected at baseline, 6 and 12 months and at the latest clinical appointment. A number of patients (63.3%) were treated with rituximab (RTX) +/- methylprednisolone in the induction phase. The expression of HLA-G in glomeruli, tubules and infiltrating cells was examined and compared between lupus patients who achieved either complete or partial renal response and those who did not respond to treatment.
RESULTS RESULTS
HLA-G staining was observed in the glomeruli of 20 of 30 samples from patients with LN. The expression of the antigen was detected in podocytes, along glomerular capillary walls, on parietal glomerular epithelial cells and within the juxtaglomerular apparatus. Seventy per cent of patients whose glomeruli expressed HLA-G achieved partial or complete response at 6 months and 75% at the latest available follow up compared with 30% and 40%, respectively, of those who did not show any expression. The pattern of staining in tubules and infiltrating cells was highly variable precluding any clinical correlation.
CONCLUSION CONCLUSIONS
This study demonstrates that HLA-G is expressed in renal tissue in LN. Our retrospective data suggest that its expression could correlate with response to treatment.

Identifiants

pubmed: 31291846
doi: 10.1177/0961203319860582
pmc: PMC7611013
mid: EMS127225
doi:

Substances chimiques

Anti-Inflammatory Agents 0
HLA-G Antigens 0
Immunologic Factors 0
Rituximab 4F4X42SYQ6
Methylprednisolone X4W7ZR7023

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1091-1100

Subventions

Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 082291
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 098476
Pays : United Kingdom

Références

Blood. 2004 Nov 15;104(10):3153-60
pubmed: 15284117
Lupus. 2009 Apr;18(5):424-30
pubmed: 19318395
Nephrol Dial Transplant. 2006 Sep;21(9):2380-90
pubmed: 16728424
Biomed Res Int. 2015;2015:318935
pubmed: 25866774
J Immunol Res. 2014;2014:657625
pubmed: 24818168
Rheumatol Int. 2015 Jun;35(6):953-61
pubmed: 25326335
Stem Cell Reports. 2015 Aug 11;5(2):248-63
pubmed: 26235895
Clin Exp Immunol. 1994 Nov;98(2):279-86
pubmed: 7955534
Stem Cells. 2008 Jan;26(1):212-22
pubmed: 17932417
J Immunol. 1990 Jan 15;144(2):731-5
pubmed: 2295808
J Immunol Res. 2014;2014:297073
pubmed: 25143957
Pharmacogenet Genomics. 2006 Sep;16(9):615-23
pubmed: 16906016
Mol Immunol. 2006 Jul;43(14):2151-60
pubmed: 16490253
Int Immunol. 1999 Jun;11(6):889-98
pubmed: 10360962
Semin Nephrol. 2012 Jul;32(4):357-67
pubmed: 22958490
Circulation. 2008 Sep 30;118(14 Suppl):S58-64
pubmed: 18824770
Curr Dir Autoimmun. 2004;7:165-80
pubmed: 14719380
Tissue Antigens. 2011 Jun;77(6):540-5
pubmed: 21395561
J Rheumatol. 2013 Jul;40(7):1104-13
pubmed: 23678155
Proc Natl Acad Sci U S A. 2001 Oct 9;98(21):12150-5
pubmed: 11572934
Arthritis Rheum. 2012 Aug;64(8):2677-86
pubmed: 22553077
J Am Soc Nephrol. 2005 Jan;16(1):175-9
pubmed: 15548564
J Clin Immunol. 2011 Jun;31(3):369-78
pubmed: 21188486
Clin Exp Med. 2013 May;13(2):135-42
pubmed: 22562117
Kidney Int. 2015 Nov;88(5):999-1012
pubmed: 25993321
Cell Mol Biol (Noisy-le-grand). 2015 Dec 09;61(8):24-30
pubmed: 26667769
Transpl Immunol. 2008 Feb;18(4):361-7
pubmed: 18158124
Hum Immunol. 2003 Nov;64(11):1039-44
pubmed: 14602233
Kidney Int. 2004 Feb;65(2):521-30
pubmed: 14717922
Transplant Proc. 2001 May;33(3):2277-80
pubmed: 11377528
Nephrol Dial Transplant. 2015 Oct;30(10):1674-83
pubmed: 26058593
J Immunol. 2011 Feb 1;186(3):1849-60
pubmed: 21187439
Hum Immunol. 2014 Dec;75(12):1171-6
pubmed: 25454623
Arthritis Rheum. 1997 Sep;40(9):1725
pubmed: 9324032
Proc Natl Acad Sci U S A. 1992 May 1;89(9):3947-51
pubmed: 1570318
Immunogenetics. 2003 May;55(2):63-79
pubmed: 12712263
Tissue Antigens. 2009 Sep;74(3):213-21
pubmed: 19531101
Int Immunopharmacol. 2017 Mar;44:234-241
pubmed: 28129605
Tissue Antigens. 2008 Jun;71(6):520-9
pubmed: 18380776
Hum Immunol. 2008 Jan;69(1):9-15
pubmed: 18295670
Ann Rheum Dis. 2013 Aug;72(8):1280-6
pubmed: 23740227
Am J Pathol. 2009 Nov;175(5):1896-904
pubmed: 19834059

Auteurs

V Foschi (V)

1 Department of Medical Sciences, Section of Rheumatology, University of Ferrara, Italy.
2 Centre for Complement and Inflammation Research, Imperial College London, UK.

D Bortolotti (D)

3 Department of Medical Sciences, Section of Microbiology and Medical Genetics, University of Ferrara, Italy.

A F Doyle (AF)

2 Centre for Complement and Inflammation Research, Imperial College London, UK.

V Stratigou (V)

2 Centre for Complement and Inflammation Research, Imperial College London, UK.

L Stephens (L)

2 Centre for Complement and Inflammation Research, Imperial College London, UK.

P Trivedi (P)

4 Department of Pathology, Imperial College Healthcare NHS Trust, Hammersmith Hospital, London, UK.

R Rinaldi (R)

5 Section of Pathology and Biomolecular Diagnostics, Department of Morphology, Surgery and Experimental Medicine, University of Ferrara, Italy.

M Padovan (M)

1 Department of Medical Sciences, Section of Rheumatology, University of Ferrara, Italy.

A Bortoluzzi (A)

1 Department of Medical Sciences, Section of Rheumatology, University of Ferrara, Italy.

L Lightstone (L)

6 Section of Renal and Vascular Inflammation, Department of Medicine, Imperial College London, UK.
7 Renal and Transplant Centre, Imperial College Healthcare NHS Trust, Hammersmith Hospital, London, UK.

T D Cairns (TD)

7 Renal and Transplant Centre, Imperial College Healthcare NHS Trust, Hammersmith Hospital, London, UK.

M Botto (M)

2 Centre for Complement and Inflammation Research, Imperial College London, UK.

T H Cook (TH)

2 Centre for Complement and Inflammation Research, Imperial College London, UK.

R Rizzo (R)

3 Department of Medical Sciences, Section of Microbiology and Medical Genetics, University of Ferrara, Italy.

M Govoni (M)

1 Department of Medical Sciences, Section of Rheumatology, University of Ferrara, Italy.

M C Pickering (MC)

2 Centre for Complement and Inflammation Research, Imperial College London, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH